Aaron Ondrey, newly appointed Chief Financial Officer of Syndax Pharmaceuticals Inc, filed an initial statement of beneficial ownership with the SEC on November 12, 2026, reporting no securities beneficially owned as of the event date of November 9, 2026.

Key Highlights

  • Reporting person: Aaron Ondrey, identified in the filing as Chief Financial Officer of Syndax Pharmaceuticals Inc (NASDAQ:SNDX).
  • Event date: The date of the event requiring the statement is listed as November 9, 2026.
  • Filing date: The form was filed on November 12, 2026, signed by Michael A. Metzger as Attorney-in-Fact.
  • No securities held: The filing states, "No securities are beneficially owned," covering both non-derivative and derivative securities.
  • Individual filing: The form was filed by one reporting person, not a joint or group filing.

Ondrey Aaron's Initial Ownership Disclosure at Syndax Pharmaceuticals

Aaron Ondrey submitted a Form 3 - Initial Statement of Beneficial Ownership of Securities - to the U.S. Securities and Exchange Commission on November 12, 2026, in connection with his role as Chief Financial Officer at Syndax Pharmaceuticals Inc. According to the filing, the event requiring the statement occurred on November 9, 2026. The form was filed pursuant to Section 16(a) of the Securities Exchange Act of 1934.

Both Table I, covering non-derivative securities such as common stock, and Table II, covering derivative securities such as options and warrants, were left blank. The filing explicitly states that "No securities are beneficially owned," indicating that Ondrey held no direct or indirect beneficial ownership in Syndax Pharmaceuticals securities as of the event date. The form was signed by Michael A. Metzger, identified as Attorney-in-Fact, on November 12, 2026.

The filing lists Ondrey's address as 730 Third Avenue, Floor 9, New York, New York 10017. His relationship to the issuer is designated solely as an officer in the capacity of Chief Financial Officer. No directorship or 10% ownership affiliation was indicated.

What Was Disclosed

Aaron Ondrey, Chief Financial Officer of Syndax Pharmaceuticals Inc (NASDAQ:SNDX), filed an initial beneficial ownership statement dated November 9, 2026, reporting no beneficially owned securities of any class, either directly or indirectly.